Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression
Adams, R. A.
Braun, Michael S
Edelstein, D. L.
Jones, F. S.
Saunders, Mark P
AffiliationDepartment of Medical & Clinical Oncology, The Christie Hospital, 550 Wilmslow Road, Manchester M20 4BX
MetadataShow full item record
AbstractAim: To determine the concordance between plasma and tissue RAS mutation status in metastatic colorectal cancer patients to gauge whether blood-based testing is a viable alternative. We also evaluated the change in mutation status on progression. Materials/methods: RAS testing was performed on plasma from patients commencing first-line therapy (OncoBEAM™ RAS CEIVD kit). Results were then compared with formalin-fixed paraffin embedded tumor samples. Results: The overall percentage agreement (concordance) was 86.0% (86/100), which demonstrates that blood-based testing is an alternative to tissue-based testing. Reproducibility was 100% between three laboratories and 20% showed changes in their RAS mutational status on progression. Conclusion: These results show good concordance between tissue and plasma samples and suggest the need for longitudinal plasma testing during treatment to guide management decisions. Keywords: BEAMing; RAS; circulating-free DNA; colon cancer; ctDNA; mCRC.
CitationGermetaki T, Nicholls C, Adams RA, Braun M, Rogan J, Moghadam S, et al. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncol. 2020.